Nanomedicine News RSS Feed - Nanomedicine

Tekmira to Provide RNAi Based Investigational Therapeutic for Clinical Studies in West Africa

Tekmira to Provide RNAi Based Investigational Therapeutic for Clinical Studies in West Africa

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that it is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa. [More]
FDA Authorizes Tekmira to Provide Treatment to Subjects with Confirmed/Suspected Ebola Virus Infections

FDA Authorizes Tekmira to Provide Treatment to Subjects with Confirmed/Suspected Ebola Virus Infections

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced that the FDA has authorized Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections. [More]
New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

New Tumor-Microenvironment-On-Chip Device Tests Effectiveness of Nanoparticles

Researchers have developed a chip capable of simulating a tumor's "microenvironment" and plan to use the new system to test the effectiveness of nanoparticles and drugs that target cancer. [More]
NANOBIOTIX Opens First US Office in Boston, Massachusetts

NANOBIOTIX Opens First US Office in Boston, Massachusetts

NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences. [More]
Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetic nanoparticles don’t have to be "one size fits all." Instead, individual magnetic nanoparticles can be tailored in an array of differing sizes and compositions to allow for heating them separately by varying the frequency and amplitude of an external alternating magnetic field, MIT graduate student Michael G. Christiansen and colleagues show in a recent Applied Physics Letters paper. [More]
Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

Bioluminescence, nanoparticles, gene manipulation – these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]
3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity. [More]
Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy women in the third trimester of pregnancy. [More]
Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced a partnership with CytImmune to manufacture CYT-6091 for injection in preparation for Phase II clinical trials. [More]
CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease. [More]